Determination of biomarkers is a very interesting approach to differentiate between the mild and severe cases of COVID-19 based on the determination of biomarkers from detailed metabolome or proteome investigations. The study will include COVID-19 confirmed patients with mild and typical respiratory tract symptoms as nonsevere group and patients with respiratory distress or multi-organ failure as severe groups.
Accessibility Controls
